JP2015522037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522037A5 JP2015522037A5 JP2015520651A JP2015520651A JP2015522037A5 JP 2015522037 A5 JP2015522037 A5 JP 2015522037A5 JP 2015520651 A JP2015520651 A JP 2015520651A JP 2015520651 A JP2015520651 A JP 2015520651A JP 2015522037 A5 JP2015522037 A5 JP 2015522037A5
- Authority
- JP
- Japan
- Prior art keywords
- vemurafenib
- theta
- degrees
- choline salt
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960003862 vemurafenib Drugs 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000004381 Choline salt Substances 0.000 claims 13
- 235000019417 choline salt Nutrition 0.000 claims 13
- -1 Vemurafenib choline salt Chemical class 0.000 claims 12
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 12
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 239000007790 solid phase Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667769P | 2012-07-03 | 2012-07-03 | |
| US61/667,769 | 2012-07-03 | ||
| PCT/US2013/049082 WO2014008270A1 (en) | 2012-07-03 | 2013-07-02 | Solid state form of vemurafenib choline salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522037A JP2015522037A (ja) | 2015-08-03 |
| JP2015522037A5 true JP2015522037A5 (enExample) | 2016-08-18 |
Family
ID=48794226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520651A Withdrawn JP2015522037A (ja) | 2012-07-03 | 2013-07-02 | ベムラフェニブコリン塩の固体形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9221815B2 (enExample) |
| EP (1) | EP2870154A1 (enExample) |
| JP (1) | JP2015522037A (enExample) |
| CN (1) | CN104470920A (enExample) |
| EA (1) | EA201590041A1 (enExample) |
| WO (1) | WO2014008270A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105008356A (zh) | 2013-03-14 | 2015-10-28 | 拉蒂奥法姆有限责任公司 | 固态形式的盐酸威罗菲尼 |
| CZ2013943A3 (cs) * | 2013-11-27 | 2015-06-03 | Zentiva, K.S. | Krystalické formy vemurafenibu |
| WO2016083956A1 (en) | 2014-11-29 | 2016-06-02 | Shilpa Medicare Limited | Substantially pure vemurafenib and its salts |
| EP3072528B1 (en) | 2015-03-26 | 2017-07-05 | ratiopharm GmbH | Composition comprising vemurafenib and cationic copolymer based on methacrylates |
| WO2017098336A1 (en) * | 2015-12-11 | 2017-06-15 | Laurus Labs Private Limited | Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof |
| WO2018002888A1 (en) | 2016-06-29 | 2018-01-04 | Halo Life Science, Llc | Methods of making low odor choline salts of an organic compound |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| PL3631017T3 (pl) * | 2017-05-25 | 2022-09-26 | Liquid Biopsy Research LLC | Sposoby wykrywania czerniaka |
| EP3860598B1 (en) | 2018-10-03 | 2023-09-06 | Jyväskylän Yliopisto | Vemurafenib and salts thereof for use in the treatment of enteroviral infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| HUE027598T2 (en) | 2009-04-03 | 2016-10-28 | Hoffmann La Roche | Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (zh) * | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
-
2013
- 2013-07-02 CN CN201380035844.3A patent/CN104470920A/zh active Pending
- 2013-07-02 EP EP13737761.0A patent/EP2870154A1/en not_active Withdrawn
- 2013-07-02 EA EA201590041A patent/EA201590041A1/ru unknown
- 2013-07-02 US US14/412,039 patent/US9221815B2/en active Active
- 2013-07-02 JP JP2015520651A patent/JP2015522037A/ja not_active Withdrawn
- 2013-07-02 WO PCT/US2013/049082 patent/WO2014008270A1/en not_active Ceased
-
2015
- 2015-11-18 US US14/944,806 patent/US20160068530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518266A5 (enExample) | ||
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| JP2013237682A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2013543867A5 (enExample) | ||
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2013522326A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2016128501A5 (enExample) | ||
| JP2018520205A5 (enExample) | ||
| JP2014527042A5 (enExample) | ||
| RU2014102773A (ru) | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv | |
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| JP2015522589A5 (enExample) | ||
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| RU2012146517A (ru) | Соли ральтегравира и их кристаллические формы | |
| JP2014530818A5 (enExample) | ||
| HRP20241280T1 (hr) | Kruti oblici rukapariba i soli rukapariba | |
| JP2020536893A5 (enExample) | ||
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2014530181A5 (enExample) |